These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 29952701

  • 21. Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis.
    Strand V, Tundia N, Song Y, Macaulay D, Fuldeore M.
    J Manag Care Spec Pharm; 2018 Apr; 24(4):344-352. PubMed ID: 29578852
    [Abstract] [Full Text] [Related]

  • 22. Minimal clinically important difference (MCID) for work productivity and activity impairment (WPAI) questionnaire in psoriasis patients.
    Wu JJ, Lin C, Sun L, Goldblum O, Zbrozek A, Burge R, Augustin M, Feldman SR.
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):318-324. PubMed ID: 29846976
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan.
    Imafuku S, Nakano A, Dakeshita H, Li J, Betts KA, Guerin A.
    J Dermatolog Treat; 2018 Feb; 29(1):24-31. PubMed ID: 28608740
    [Abstract] [Full Text] [Related]

  • 25. Cost effectiveness of biologic therapies for plaque psoriasis.
    Ahn CS, Gustafson CJ, Sandoval LF, Davis SA, Feldman SR.
    Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
    [Abstract] [Full Text] [Related]

  • 26. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
    Reich K, Papp KA, Blauvelt A, Langley RG, Armstrong A, Warren RB, Gordon KB, Merola JF, Okubo Y, Madden C, Wang M, Cioffi C, Vanvoorden V, Lebwohl M.
    Lancet; 2021 Feb 06; 397(10273):487-498. PubMed ID: 33549193
    [Abstract] [Full Text] [Related]

  • 27. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.
    Al Sawah S, Foster SA, Burge R, Amato D, Schacht A, Zhu B, Hartz S, Leonardi C.
    J Med Econ; 2017 Dec 06; 20(12):1224-1230. PubMed ID: 28760056
    [Abstract] [Full Text] [Related]

  • 28. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
    Kokolakis G, Warren RB, Strober B, Blauvelt A, Puig L, Morita A, Gooderham M, Körber A, Vanvoorden V, Wang M, de Cuyper D, Madden C, Nunez Gomez N, Lebwohl M.
    Br J Dermatol; 2023 Feb 22; 188(3):330-340. PubMed ID: 36751950
    [Abstract] [Full Text] [Related]

  • 29. Impact of fixed-dose combination Cal/BD foam on the work productivity of patients with psoriasis: results from the 52-week randomized, double-blind, PSO-LONG trial.
    Guenther L, Takhar A, Megna M, Sebastian M, Nyholm N, Thoning H, Levin LÅ.
    J Eur Acad Dermatol Venereol; 2022 Jul 22; 36(7):1054-1063. PubMed ID: 35297108
    [Abstract] [Full Text] [Related]

  • 30. Work productivity and healthcare resource utilization outcomes for patients on etanercept for moderate-to-severe plaque psoriasis: results from a 1-year, multicentre, open-label, single-arm study in a clinical setting.
    Vender R, Lynde C, Ho V, Chau D, Poulin-Costello M.
    Appl Health Econ Health Policy; 2012 Sep 01; 10(5):343-53. PubMed ID: 22877226
    [Abstract] [Full Text] [Related]

  • 31. Characteristics and Medication Use of Psoriasis Patients Who May or May Not Qualify for Randomized Controlled Trials.
    Malatestinic W, Nordstrom B, Wu JJ, Goldblum O, Solotkin K, Lin CY, Kistler K, Fraeman K, Johnston J, Hawley LL, Sicignano N, Araujo A.
    J Manag Care Spec Pharm; 2017 Mar 01; 23(3):370-381. PubMed ID: 28230450
    [Abstract] [Full Text] [Related]

  • 32. How much of the productivity losses among psoriasis patients are due to psoriasis.
    Mustonen A, Mattila K, Leino M, Koulu L, Tuominen R.
    BMC Health Serv Res; 2015 Mar 04; 15():87. PubMed ID: 25888995
    [Abstract] [Full Text] [Related]

  • 33. Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit.
    Fendrick AM, Brixner D, Rubin DT, Mease P, Liu H, Davis M, Mittal M.
    J Manag Care Spec Pharm; 2021 Aug 04; 27(8):1086-1095. PubMed ID: 33843252
    [Abstract] [Full Text] [Related]

  • 34. Costs Associated with Productivity Loss Among U.S. Patients Newly Diagnosed with Multiple Myeloma Receiving Oral Versus Injectable Chemotherapy.
    Merola D, Yong C, Noga SJ, Shermock KM.
    J Manag Care Spec Pharm; 2018 Oct 04; 24(10):1019-1026. PubMed ID: 30247101
    [Abstract] [Full Text] [Related]

  • 35. Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial.
    Blauvelt A, Lomaga M, Burge R, Zhu B, Shen W, Shrom D, Dossenbach M, Pinter A.
    J Dermatolog Treat; 2020 Mar 04; 31(2):141-146. PubMed ID: 30799638
    [Abstract] [Full Text] [Related]

  • 36. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
    Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM.
    Am J Clin Dermatol; 2011 Feb 01; 12(1):51-62. PubMed ID: 21110526
    [Abstract] [Full Text] [Related]

  • 37. Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3.
    Warren RB, Hansen JB, Reich K, Paul C, Puig L.
    J Eur Acad Dermatol Venereol; 2021 Feb 01; 35(2):450-457. PubMed ID: 32662540
    [Abstract] [Full Text] [Related]

  • 38. Impact of etanercept on work and activity impairment in employed moderate to severe rheumatoid arthritis patients in the United States.
    Hone D, Cheng A, Watson C, Huang B, Bitman B, Huang XY, Gandra SR.
    Arthritis Care Res (Hoboken); 2013 Oct 01; 65(10):1564-72. PubMed ID: 23554320
    [Abstract] [Full Text] [Related]

  • 39. Work productivity in real-life employed patients with plaque psoriasis: Results from the ProLOGUE study.
    Saeki H, Kanai Y, Murotani K, Ito K, Miyagi T, Takahashi H, Tada Y, Higashiyama M, Hashimoto Y, Kitabayashi H, Imafuku S.
    J Dermatol; 2022 Oct 01; 49(10):970-978. PubMed ID: 35856276
    [Abstract] [Full Text] [Related]

  • 40. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
    Abrouk M, Nakamura M, Zhu TH, Farahnik B, Koo J, Bhutani T.
    J Dermatolog Treat; 2017 Sep 01; 28(6):488-491. PubMed ID: 28042711
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.